View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Rheumatology (Oxford). 2024 Oct 10:keae549 doi 10.1093/rheumatology/keae549 Epub ahead of print
Delcourt et al. conducted a systematic review and meta-analysis revealing that both pharmacological (DMARDs) and non-pharmacological interventions reduce fatigue in axSpA patients over short and medium terms, with greater efficacy seen when combined.
Clin Rheumatol 2024;43(3):1045–1052 doi: 10.1007/s10067-023-06849-5
The results of the meta-analysis show that TNFi, IL-17i, and JAK inhibitor treatments significantly improved sacroiliac joint SPARCC scores in patients with axSpA or AS at Weeks 12–16. However, there were no significant differences in mean improvement between the treatment groups.
RMD Open. 2024; 10(1):e003942 DOI 10.1136/rmdopen-2023-003942
Patients in France who started secukinumab therapy further from the launch of secukinumab were more likely to receive it as a first- or second-line therapy than patients who started treatment shortly after its launch, and had a higher retention rate when used as a first line treatment.
RMD Open 2023;9:e002802 doi: 10.1136/rmdopen-2022-002802
This study reported the overall retention of secukinumab in daily practice in the period following its approval in France was approximately 59% at 1 year in axSpA patients. The aim of this study was to determine whether OSI were predictive of secukinumab retention at 1 year.
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead072
MACEs were observed in patients newly receiving compensation from the Long-term Illness Scheme for AS. The objective of this study was to describe the incidence of MACEs in French patients newly benefiting from the French LTI for AS. The study also sought to evaluate the effect of various treatments on the risk of MACE occurrence.
